Athena Athena

X
[{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"ISOThrive Awarded $800K Virginia Catalyst Grant to address major unmet need in gastroesophageal reflux disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by ISOThrive

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ISOThrive is studying maltosyl-isomaltooligosaccharide for the treatment of GERD, and potential for reducing risk of Barrett's Esophagus and esophageal adenocarcinoma in collaboration with Eastern VA Medical School, University of VA and George Mason University.

            Lead Product(s): Maltosyl-isomaltooligosaccharide

            Therapeutic Area: Gastroenterology Product Name: MIMO

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Virginia Catalyst

            Deal Size: $0.8 million Upfront Cash: Undisclosed

            Deal Type: Funding October 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY